For years, Elmiron® (pentotan polysulfate sodium) has been the only drug approved by the Food & Drug Administration to treat interstitial cystitis, which is an extremely painful chronic bladder condition. Unfortunately, researchers have now discovered a clear link between the use of Elmiron® and a new progressive eye disorder known as pigmentary maculopathy. This condition directly affects the pigment of the eye – and can cause impaired vision and even blindness after long-term use.
At Wagner Reese, our defective drug lawyers have spent decades helping clients who were severely harmed by medications. In general, we trust that our medications will be rigorously tested and screened by the pharmaceutical companies that produce them. When these companies fail to consider public health and safety, it’s important to hold them accountable for the injuries that they cause. By representing your interests in the legal process, our team can help you pursue a fair outcome.
For more information on how we can help you with an Elmiron® eye damage lawsuit in Indianapolis or beyond, we invite you to call our legal team at (888) 204-8440 today.
What Are the Signs and Symptoms of Pigmentary Maculopathy?
In 2018, a clinical study published in the journal Ophthalmology first indicated that patients who took pentotan polysulfate sodium (PPS) suffered from retinal damage and a “novel and possibly avoidable maculopathy” associated with the drug. Over the next few years, several other clinical studies reinforced this finding, with one Kaiser Permanente study discovering that 25% of patients who took Elmiron® showed evidence of retinal damage, which was often misdiagnosed as age-related macular degeneration or pattern dystrophy.
When patients have pigmentary maculopathy, they often report the following symptoms and signs:
- Blurred or “halo” vision
- Dimmed vision
- Difficulty adjusting to light and darkness
- Spots in the central vision field
- Straight lines appearing squiggly or curved
- Loss of color perception and less vivid colors
- Blindness and loss of vision
So far, it is believed that pigmentary maculopathy is uniquely caused by the use of pentotan polysulfate sodium. Researchers have also found that patients may continue to develop vision loss and eye damage even after they stop taking the drug altogether. With more than 1 million patients who suffer from interstitial cystitis in the U.S. alone, this means that hundreds of thousands of people could be at risk of lasting eye damage and the lost opportunities it brings.
What Can I Do After Suffering Eye Damage?
Blindness is a serious, life-altering disability, and it can be incredibly traumatic for victims to experience the gradual loss of their vision over time. Aside from the medical expenses and psychological toll associated with these injuries, victims may not be able to keep working in their fields, preventing them from earning income for their families or continuing in their chosen careers.
While Janssen Pharmaceuticals – the manufacturer and seller of Elmiron® – has now officially added a warning label about pigmentary maculopathy to the drug, many more patients could develop eye damage and vision loss as a result of taking Elmiron® for years. Our Indianapolis attorneys at Wagner Reese are committed to representing those who have suffered these losses and holding Janssen accountable for failing to warn about this dangerous side effect.
We are here to hear your story. Call us at (888) 204-8440 today to schedule a free consultation.